ReviewThe International journal of angiology : official publication of the International College of Angiology, Inc2025
A Review of Indications and Guidelines of Chronic Total Occlusion Revascularization.
Review in The International journal of angiology : official publication of the International College of Angiology, Inc, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Predictors of Major Adverse Cerebrovascular and Cardiac Events After Successful Transradial Chronic Total Occlusion Recanalization: Five-Year Results of the TRACTOR Study.Journal of personalized medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic total occlusion (CTO), affecting 18 to 30% of coronary artery disease patients undergoing angiography, is linked to refractory angina, reduced left ventricular function, and increased arrhythmia risk. This article synthesizes indications, evidence, and guidelines for CTO revascularization, focusing on percutaneous coronary intervention (PCI). CTO PCI achieves over 85% success rates in expert hands, with randomized controlled trials showing improved symptom relief and quality of life, though mortality or ventricular function benefits remain unproven. The 2021 ACC/AHA/SCAI and 2018 ESC/EACTS guidelines recommend CTO PCI for refractory angina, emphasizing operator expertise and shared decision-making. Controversies persist regarding prognostic benefits and patient selection. Ongoing trials aim to clarify these issues. This review equips clinicians with a framework to navigate CTO management, balancing evidence and patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.